WebFimecs has raised a total of ¥810M in funding over 2 rounds. Their latest funding was raised on May 28, 2024 from a Series A round. Fimecs is funded by 5 investors. ANRI and UTokyo Innovation Platform are the most recent investors. Funding Rounds Number of Funding Rounds 2 Total Funding Amount ¥810M WebMar 6, 2024 · According to ZoomInfo records, Yusuke Tominari’s professional experience began in 2005. Since then Yusuke has changed 2 companies and 2 roles. Currently, …
KPMG announces the winner of the GTI 2024 - KPMG Global
WebFIMECS, Inc. is developing a new class of drugs based on emerging modality “Targeted Protein Degradation”. Integrating proprietary E3 ligase binders and RaPPIDS™ platform will enable to address previously considered undruggable targets and to provide game-changing drugs to the patients with high unmet medical needs. WebWe use powerful chemical screens that enable new classes of small molecule drugs to target mutant proteins with specificity. We harness the power of protein degradation for … media markt greece english
Japan Biotech Startups Directory 2024: Establishment,
WebLegal Name Fimecs Inc. Company Type For Profit Contact Email [email protected] Phone Number +81-466-32-1169 FIMECS is a protein degradation technology-based drug … Webファイメクス株式会社 (FIMECS, Inc.) 〒251-0012 神奈川県藤沢市村岡東二丁目26番地の1 TEL : 0466-96-0261. Follow Us. お問い合わせ; 採用情報; プライバシーポリシー WebFIMECS, Inc., National Center for Genetic Engineering and Biotechnology (BIOTEC) Introduction and Background of the Project 1. Introduction Malaria is one of the most widespread infectious diseases in which over 200 million infections occur annually worldwide. Current antimalarial drugs do not work well against malarial parasite. pendl gasthof